{"name":"Surface Ophthalmics, Inc.","slug":"surface-ophthalmics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Betamethasone Sodium Phosphate 0.01%","genericName":"Betamethasone Sodium Phosphate 0.01%","slug":"betamethasone-sodium-phosphate-0-01","indication":"Treatment of ocular inflammation and uveitis","status":"phase_2"}]}],"pipeline":[{"name":"Betamethasone Sodium Phosphate 0.01%","genericName":"Betamethasone Sodium Phosphate 0.01%","slug":"betamethasone-sodium-phosphate-0-01","phase":"phase_2","mechanism":"Betamethasone sodium phosphate is a corticosteroid that reduces inflammation and suppresses the immune system.","indications":["Treatment of ocular inflammation and uveitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPZFBMekJPMHNUaUZINEtqSFNfdmxLN05uX0tDcmx6U0NVRGZjQ29aY2FscVZiSTc4a0YyakV5V0xpdlpCdzB3c0xjVFE2aFpEQ1Y0ajl4TW5ETHo5MV9lUGt2WkI2a09HUHpVa0l0Si1nYlZUam1rZ054cFFvTGF0NzNzNTV2MGtGMzhYV0N0TzlGV0h3em1iRjVMTUExaHc?oc=5","date":"2026-03-17","type":"pipeline","source":"Finimize","summary":"Harrow: why this fast-growing eye-care pharma stock is worth a look - Finimize","headline":"Harrow: why this fast-growing eye-care pharma stock is worth a look","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaHA2TnBLWUdpajBpellvS0UtTDMzMXMxTFhwOExIZVYxWkZySTZzR2JkTHh1cExKN2Z2eWpST05TckVqeHBGaTltSkExQ2FEa1FrTW9vYWFQSUYtVzFmQ2xnZlBDRndSOFBoTXlHMTVNSU1laV9kbjZfLURRa2JQdHgweUUyYnBObG5sTWhHUE5LOXpjV0ZGcnRIQVVpOXY1Yk1XY1FYZ3JHQQ?oc=5","date":"2026-02-06","type":"pipeline","source":"Ophthalmology Times Europe","summary":"Building a dry eye clinic around intense pulsed light treatment - Ophthalmology Times Europe","headline":"Building a dry eye clinic around intense pulsed light treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOMzNZUWplUkhuR3lmYnZibFhXcGsybFlsdzdsVEpQaHlLbFB0dV9IQXNQMWJrVEt2MktTUHJIYzhGVWQ3aEE0eG1HVHJrSHlEcVltWDRmSmFSNzVJMHc4V0xNSVY2bU9iQkRYTXpGVEhtVjU1dmNJS2xuYks5cm5MZURpMC1fQkRCQ1BVeFEzSlhQeGN3LW5pT19QYkpuNE04emZ3NE5hXzhhX3liUnI3emtwckROMWZfYXpia3g5c1pqY05NcW9qTXFmWlRPNTFzSEtZ?oc=5","date":"2025-12-10","type":"pipeline","source":"Business Wire","summary":"Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026 - Business Wire","headline":"Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPdmtSNzRBd0MyWmVSNTF2Y2pGNVZUVU5BMkFoSFA0QVdhTW9CNWx0eG5NYnhhZG5ZSWJ1enRlaW5oaWRZR0VoLURWaWN0dWdWemlFWTd5RGJ4emZjZGNtNU53NmhIdHhZaVNzMFJWUTI3NUxnMy1SdWppWkNLSUVTVElqbjFNTEZkLXJLa3k0djlBX3BWOXdCT1NudmJZb1NzOXVyeA?oc=5","date":"2025-10-08","type":"pipeline","source":"Ophthalmology Times","summary":"Ocular surface: Targeted therapies for a multifactorial problem - Ophthalmology Times","headline":"Ocular surface: Targeted therapies for a multifactorial problem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOUmQybk9TX2VZZTFLQVZuek1GNl9ZdUU2eFlSZTdVTWpqZEtLU3M2MnRVLURYT0VfWVFBMk95YTZEOHF0ZHhDZmFIcU0yWHBQUWY3TTQybWFVWmUyMkNBdlNGZ3l0TzhOSUJwZklSd0VONXFLd3RTSER4dDV5T1lkeUNrYnM4NTZzb1ZzVUFualNPV25vSXRIaXU4U2l4YjVkQUlQeE5MeWtpd3FqaHk4TVJwVWYyRS0yb0piNU9vZ2ZFUG1zdTJCWEdYbG1nQW1PNW9CWF9fWkEyY1Nwek9IenlzcERnTk96SzNxOWdvSDVGeUFXOXdZRFRrcndESU01SkNPMVN3X1pmQnQ5V1A1WllCaUhrRzJLSHVTdTY0cF80QQ?oc=5","date":"2025-09-24","type":"trial","source":"PR Newswire","summary":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPTzhDYkp5QThRMUFxZEJqZW9MbWF4b1FfN2xGMWhyT2ZONFV5LU9sLWpjMThtaVJrSkNWNUFhRldxM2c4NWJibkxhYmRwRTVDVnRhWmdmMGRGS0JJU2hQdEd3VzJuZjIzQzRtMnlsclV2SVpMS0RwX0xBNGQ5SWtmcGp4MW45M3d6VjV5U0xUTm9YVTkyVXctWkt2R2FXZkRkYTBYUHg0UGFJa2o2NzFhXzNkSUFpaTZObDRHd0xTcjY4b1E?oc=5","date":"2025-08-11","type":"trial","source":"Eyes On Eyecare","summary":"Cequa's Onset of Action Trial demonstrates rapid ocular surface benefits - Eyes On Eyecare","headline":"Cequa's Onset of Action Trial demonstrates rapid ocular surface benefits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQVFzRGxpRTF4X2xqZEdYSVh0MmlvUWY5aldoY0tsN011Uy0wZDViZXc5UEttZ1hRei1OQ25SVUlWajZaekJqSFVEMXZmYWhVTG1oVVVUXzFMb1ZzNkl4R2dmV0tuZTRrZTdyblNYeGE1ODFoQWEwT2M4TWlwbFg5VFZacDlKcjFYU19fenplUHJMaVp5eEo0cEdDbEMwdHNJd2tvTWNkaGNmb3JIX3lzQ3ZCcEVxWmpZZWhr?oc=5","date":"2025-03-01","type":"pipeline","source":"Seeking Alpha","summary":"Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha","headline":"Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOUEhkWkdJMm5TNXdGZXJhMWFZb0VyWnRxcUNtQl9Pc2ZNNlRndHlhVzl4SS14YVFZNjVJcTkybk1vb1QtTzhzTGZNek1DZnhhc0JjUm9IOVRnejZGVWRYTl81cDZJQzRfSHJqLUZIOVVrMXhMaVJHX2stRzN4RDBkSmVrR3Z4U3E0ckVZME5nbTl5aEU4WUlNWnFDUXFIc05McDM5aHRYckF3Ymd6NU04dnU5SDAyTXBPNnhreV9LMEhvU3BwXzVz?oc=5","date":"2024-03-15","type":"pipeline","source":"Eyes On Eyecare","summary":"Surface Ophthalmics appoints new leader with plans for dry eye advancements - Eyes On Eyecare","headline":"Surface Ophthalmics appoints new leader with plans for dry eye advancements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5oS2liZjZ1UDNyaER5eXp0UVZEUzRiZWxjTEQxLWdrakxWNUFvVE5RUWtiV3RZT3RoWDVma2F2bUYxVWJCSkJ0RUR4aUNmWTRDcFR1UFVzMUNucGxOd2Z1QXJXQnM3RGFWSFE?oc=5","date":"2023-03-19","type":"pipeline","source":"Wiley Online Library","summary":"Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis - Wiley Online Library","headline":"Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatmen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQaEltbENqdnY5TnZFNEZkdVBKVzMxMHRuOTlDZ3ZPaEp3LTRPZTRBbUFybzlqdmdtV3RjdTZBVnJMY0NkVlptNGxLMHZkSHF6eUZFVXQ4X0RwdnJUeEJqQnI0U1NZYThiZThsbXBERWJrYWtsbnFscTQ5bzFRcWhvRzI0aFltbTItVFFXVmtxQXhkWmxzX3BabWdUaTRXNEFlVEo0a2h1dS1SdmJoUVg4WkNDLUJiaGR0eFRiSGpqc3NUZUpXSnkwZVJQNGtLLTFYUG5Haw?oc=5","date":"2021-07-27","type":"deal","source":"Business Wire","summary":"Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica - Business Wire","headline":"Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1XeFd3d0diYXVNLTd6ZGNuTTdJTjdXODJ4S2syZjhJeTFsanY5TnF3eEw1OEFKZS1mVjFWTzZKWDVldFlPck9iZm5YVzVSQUhwdWJZOVpxNE5tSkZZRGhvWU5STFBjMHdRczFRbEZlLTl1YUZqemUwb2RWdGU?oc=5","date":"2021-01-25","type":"pipeline","source":"pharmacytimes.com","summary":"Eysuvis From Kala Pharmaceuticals, Inc - pharmacytimes.com","headline":"Eysuvis From Kala Pharmaceuticals, Inc","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}